top of page
The Professional Network for Healthcare Experts
FDA approves Lipfendra as the first oral PCSK9 inhibitor for high cholesterol
The once-daily tablet provides a new oral option for reducing LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia.
nuaxia
Jul 211 min read
Merck’s Lipfendra Becomes First FDA-Approved Oral PCSK9 Inhibitor for High Cholesterol
Oral cholesterol therapy offers an alternative to injectable PCSK9 inhibitors as Merck targets multi-billion-dollar cardiovascular market.
nuaxia
Jul 173 min read
bottom of page